312 related articles for article (PubMed ID: 26818602)
1. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
Hodge RJ; Nunez DJ
Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
[TBL] [Abstract][Full Text] [Related]
2. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1.
Kouremenou C
IDrugs; 2009 Aug; 12(8):463-4. PubMed ID: 19629873
[No Abstract] [Full Text] [Related]
3. Patented TGR5 modulators: a review (2006 - present).
Gioiello A; Rosatelli E; Nuti R; Macchiarulo A; Pellicciari R
Expert Opin Ther Pat; 2012 Dec; 22(12):1399-414. PubMed ID: 23039746
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic application of GPR119 ligands in metabolic disorders.
Yang JW; Kim HS; Choi YW; Kim YM; Kang KW
Diabetes Obes Metab; 2018 Feb; 20(2):257-269. PubMed ID: 28722242
[TBL] [Abstract][Full Text] [Related]
5. Metabolic diseases.
Balfe A; Perry L
IDrugs; 2006 Nov; 9(11):754-5. PubMed ID: 17096291
[No Abstract] [Full Text] [Related]
6. Cardiovascular effects of current and future anti-obesity drugs.
Comerma-Steffensen S; Grann M; Andersen CU; Rungby J; Simonsen U
Curr Vasc Pharmacol; 2014 May; 12(3):493-504. PubMed ID: 24846238
[TBL] [Abstract][Full Text] [Related]
7. Natural compound renews hope for diabetes and obesity therapeutic target.
Merk D; Schubert-Zsilavecz M
Future Med Chem; 2015; 7(7):833-5. PubMed ID: 26061101
[No Abstract] [Full Text] [Related]
8. Nomilin as an anti-obesity and anti-hyperglycemic agent.
Sato R
Vitam Horm; 2013; 91():425-39. PubMed ID: 23374727
[TBL] [Abstract][Full Text] [Related]
9. [New therapies for type 2 diabetes mellitus].
Puig-Domingo M; Pellitero S
Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
[TBL] [Abstract][Full Text] [Related]
10. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
Choi YJ; Shin D; Lee JY
Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
[TBL] [Abstract][Full Text] [Related]
11. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
12. Bariatric surgery reveals a gut-restricted TGR5 agonist with anti-diabetic effects.
Chaudhari SN; Harris DA; Aliakbarian H; Luo JN; Henke MT; Subramaniam R; Vernon AH; Tavakkoli A; Sheu EG; Devlin AS
Nat Chem Biol; 2021 Jan; 17(1):20-29. PubMed ID: 32747812
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of the bile acid receptor TGR5 in metabolism.
van Nierop FS; Scheltema MJ; Eggink HM; Pols TW; Sonne DP; Knop FK; Soeters MR
Lancet Diabetes Endocrinol; 2017 Mar; 5(3):224-233. PubMed ID: 27639537
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
16. Research Progress of Takeda G Protein-Coupled Receptor 5 in Metabolic Syndrome.
Gou X; Qin L; Wu D; Xie J; Lu Y; Zhang Q; He Y
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570840
[TBL] [Abstract][Full Text] [Related]
17. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Overton HA; Fyfe MC; Reynet C
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
[TBL] [Abstract][Full Text] [Related]
18. Investigational therapies in the treatment of obesity.
Mancini MC; Halpern A
Expert Opin Investig Drugs; 2006 Aug; 15(8):897-915. PubMed ID: 16859393
[TBL] [Abstract][Full Text] [Related]
19. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
20. [Pharmaco-proteomic analysis: application of proteomic analysis to the discovery and development of new drugs].
Chapal N; Laplanche M; Ribes G; Pau B; Garin J; Petit P
J Soc Biol; 2002; 196(4):317-22. PubMed ID: 12645303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
